The CEO's open-market purchase is a positive signal of conviction, but the $321K amount is modest for a $126M market cap. Monitor for additional insider buying or pipeline catalysts (Phase 2a data for foralumab) that could provide a stronger fundamental catalyst.
Price Chart
Executive Summary
Tiziana Life Sciences CEO Ivor Elrifi purchased 321,423 common shares at $1.00 per share on the open market, increasing his total holdings to 4,793,684 shares. This insider buy signals management's confidence in the company's pipeline, particularly its lead candidate intranasal foralumab for multiple sclerosis, but represents a modest $321K investment relative to the $126M market cap.
Key Facts
- CEO Ivor Elrifi purchased 321,423 common shares at $1.00 per share on August 6, 2026
- CEO's total holdings increased to 4,793,684 common shares
- Purchase was an open-market transaction on Nasdaq
- Lead candidate intranasal foralumab is in a Phase 2a trial for non-active secondary progressive multiple sclerosis
- 14 patients dosed in an Expanded Access Program with improvement or stability seen in all patients within 6 months
Financial Impact
CEO purchased $321,423 worth of shares at $1.00 per share
Risk Factors
- Clinical-stage biotech with no approved products; pipeline risk for foralumab
- Single insider buy of modest size may not be a strong signal of near-term value inflection
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-085904 |
| Document: ea030088601ex99-1.htm | 0001213900-26-085904 |
| Document: 0001213900-26-085904-index-headers.html | 0001213900-26-085904 |
| Document: 0001213900-26-085904-index.html | 0001213900-26-085904 |
| Document: 0001213900-26-085904.txt | 0001213900-26-085904 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (−12.87%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (+12.87%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8800 (−16.19%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8800 (−20.72%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8800 (−10.20%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8800 (−2.72%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8800 (−23.48%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8800 (−9.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers